Home › Schizophrenia › NCT05299749

Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations

Real-time fMRI Neurofeedback as a Tool to Mitigate Auditory Hallucinations in Patients With Schizophrenia - R33 Phase

Who can join

Ages 18 to 55 · All sexes

Inclusion Criteria:

* patients diagnosed with SZ or schizoaffective disorder using DSM-5 criteria
* auditory hallucinations not responsive to pharmacology as determined by chart review and a clinical interview of SCID.

Exclusion Criteria:

* neurologic illness
* major head trauma
* electroconvulsive therapy
* alcohol or drug dependence
* alcohol or drug abuse within the past five years
* verbal IQ below 70

About the study

Neurofeedback intervention aimed to regulate the superior temporal gyrus (STG) activation and default mode network (DMN) connectivity as well as to reduce the auditory hallucinations (AH) schizophrenia patients with medication resistant AH.

What is being tested

• stg-rt-fMRI-Neurofeeback (other)
• sham-rt-fMRI-Neurofeedback (other)

Sponsor: Boston VA Research Institute, Inc. · Participants: 104 · Started: Mar 1, 2022

Contact the study team

• margaret niznikiewicz, PhD · Phone: 6176534627
• Clemens Bauer, phd · Phone: 617-870-1771

Official record on ClinicalTrials.gov — NCT05299749

Locations in the U.S.

Conditions

• Schizophrenia
• Hallucinations

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.